Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma

Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy

(2012) H. K. Gan et al.   CANCER RESEARCH

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas

(2012) Catherine A Del Vecchio et al.   Expert Review of Vaccines

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

(2012) David F Stroncek et al.   Journal of Translational Medicine

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Two signal models in innate immunity

(2011) Mary F. Fontana et al.   IMMUNOLOGICAL REVIEWS

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Development of an EGFRvIII specific recombinant antibody

(2010) Puja Gupta et al.   BMC BIOTECHNOLOGY

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

(2010) Masasuke Ohno et al.   CANCER SCIENCE

Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor   Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors

(2010) A. S. Y. Lo et al.   CLINICAL CANCER RESEARCH

4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies

(2009) Syam Tammana et al.   HUMAN GENE THERAPY

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

(2009) Szofia S. Bullain et al.   JOURNAL OF NEURO-ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA